CAT

872.43

+1.39%↑

299.94

+5.33%↑

GEV.US

1,023.5

+1.19%↑

RTX

175.21

+0.4%↑

222.27

+3.4%↑

CAT

872.43

+1.39%↑

299.94

+5.33%↑

GEV.US

1,023.5

+1.19%↑

RTX

175.21

+0.4%↑

222.27

+3.4%↑

CAT

872.43

+1.39%↑

299.94

+5.33%↑

GEV.US

1,023.5

+1.19%↑

RTX

175.21

+0.4%↑

222.27

+3.4%↑

CAT

872.43

+1.39%↑

299.94

+5.33%↑

GEV.US

1,023.5

+1.19%↑

RTX

175.21

+0.4%↑

222.27

+3.4%↑

CAT

872.43

+1.39%↑

299.94

+5.33%↑

GEV.US

1,023.5

+1.19%↑

RTX

175.21

+0.4%↑

222.27

+3.4%↑

Kodu・Aktsiate loetelu・Ocugen Inc

Ocugen Inc

Suletud

1.35 4.65

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.3

Max

1.3599999999999999

Põhinäitajad
By Trading Economics
Sissetulek	-1.5M -19M
Müük	1.7M 1.5M
Aktsiakasum	-0.06
Kasumimarginaal	-1,250.946
Töötajad	116
EBITDA	-987K -17M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+790% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	31. juuli 2026

Turustatistika
By TradingEconomics
Turukapital	-173M 454M
Eelmine avamishind	-3.3
Eelmine sulgemishind	1.35

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

0.6818 / 0.74 Toetus ja vastupanu

Ocugen Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

19. mai 2026, 20:36 UTC

Omandamised, ülevõtmised, äriostud

Analog Devices to Buy Empower Semiconductor for $1.5 Billion

19. mai 2026, 23:47 UTC

Market Talk

Nikkei May Decline as Concerns About Energy, Material Costs Persists -- Market Talk

19. mai 2026, 23:34 UTC

Market Talk

Gold Edges Higher on Possible Technical Recovery -- Market Talk

19. mai 2026, 23:28 UTC

Market Talk

Tulu

Global Forex and Fixed Income Roundup: Market Talk

19. mai 2026, 23:28 UTC

Market Talk

Tulu

F&P Healthcare's Outlook Key for Investors -- Market Talk

19. mai 2026, 23:10 UTC

Market Talk

Global Equities Roundup: Market Talk

19. mai 2026, 23:10 UTC

Market Talk

Kiwi Property's Dividend Growth Reliant on Several Factors -- Market Talk

19. mai 2026, 22:02 UTC

Tulu

ZTO Express (Cayman): Di Xu to Resign From Board

19. mai 2026, 22:01 UTC

Tulu

ZTO Express (Cayman) 1Q Adj EPS 43c >ZTO

19. mai 2026, 22:01 UTC

Tulu

ZTO Express (Cayman) 1Q EPS 39c >ZTO

19. mai 2026, 22:00 UTC

Tulu

ZTO Express (Cayman) 1Q Rev $1.93B >ZTO

19. mai 2026, 21:37 UTC

Tulu

Cracks Are Starting to Appear in the Chip Stock Rally -- Barrons.com

19. mai 2026, 21:31 UTC

Omandamised, ülevõtmised, äriostud

How NextEra Can Fix Dominion's Strange AI Problem -- Barrons.com

19. mai 2026, 21:01 UTC

Tulu

Home Depot Beats Earnings Estimates as Shoppers Defy Inflation Fears. The Stock Advances. -- Barrons.com

19. mai 2026, 20:58 UTC

Tulu

These Stocks Are Today's Movers: CoreWeave, Nvidia, Home Depot, Akamai, Agilysys, Micron, and More -- Barrons.com

19. mai 2026, 20:46 UTC

Kuumad aktsiad

Stocks to Watch Recap: ServiceNow, Home Depot, CoreWeave -- WSJ

19. mai 2026, 20:43 UTC

Market Talk

Canada 30-Year Yield Hits Highest Level Since 2010 -- Market Talk

19. mai 2026, 20:34 UTC

Tulu

James Hardie Industries Sees FY27 Sales $5.25B-$5.41B >JHX

19. mai 2026, 20:32 UTC

Tulu

James Hardie Industries: Targeting Pro Forma Adjusted EBITDA Growth of 4% to 8% in FY27 >JHX

19. mai 2026, 20:32 UTC

Tulu

James Hardie Industries 4Q EPS 5c >JHX

19. mai 2026, 20:32 UTC

Tulu

James Hardie Industries 4Q Sales $1.4B >JHX

19. mai 2026, 20:21 UTC

Omandamised, ülevõtmised, äriostud

Analog Devices to Buy Empower Semiconductor for $1.5B

19. mai 2026, 20:18 UTC

Market Talk

Canada CPI Data Has Accounting Quirk Related to Travel Tours -- Market Talk

19. mai 2026, 20:13 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

19. mai 2026, 20:13 UTC

Market Talk

'Hard to Square' Canada Rate Hikes Expectations Given Mild Core -- Market Talk

19. mai 2026, 20:03 UTC

Omandamised, ülevõtmised, äriostud

Analog Devices: Deal Further Advances Position as Strategic, System-Level Grid-To-Core Power Partner for Hyperscalers, AI Silicon Developers >ADI

19. mai 2026, 20:03 UTC

Omandamised, ülevõtmised, äriostud

Analog Devices: Phillips Will Continue Leading IVR Technology Efforts as Part of ADI >ADI

19. mai 2026, 20:02 UTC

Omandamised, ülevõtmised, äriostud

Analog Devices Will Acquire Empower in All-Cash Transaction for $1.5 B >ADI

19. mai 2026, 20:02 UTC

Omandamised, ülevõtmised, äriostud

Analog Devices to Acquire Empower Semiconductor, Expanding Its Next-Generation High-Density Power Portfolio for the AI Era

19. mai 2026, 19:23 UTC

Market Talk

Oil Futures Slip With Market Back on U.S.-Iran Deal Watch -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Ocugen Inc Prognoos

Hinnasiht

By TipRanks

790% tõus

12 kuu keskmine prognoos

Keskmine 11.57 USD 790%

Kõrge 22 USD

Madal 7 USD

Põhineb 7 Wall Streeti analüütiku instrumendi Ocugen Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

7 ratings

Osta

Hoia

Müü

Põhineb 7 analüütiku instrumendi Ocugen Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.6818 / 0.74Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There are no events.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.